23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Active as of 2024-11-21

Generated Narrative: Citation 179629

version: 10; Last updated: 2024-07-18 17:58:40+0000

Profile: JournalArticleCitation

url: Citation 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

identifier: FEvIR Object Identifier/179629, https://pubmed.ncbi.nlm.nih.gov/23604530, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.2

version: 2.0.0-ballot

title: 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

status: Active

date: 2024-11-21 14:09:14+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

Code

Value[x]

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Medline Base

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2013-08-01

lastReviewDate: 2021-11-22

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification
type: Citation Source
classifier: MEDLINE

classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2013-02-14

statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2013-04-08

statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2013-04-23 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2013-04-23 06:00:00+0000

statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2013-08-02 06:00:00+0000

citedArtifact
identifier: https://pubmed.ncbi.nlm.nih.gov/23604530, https://doi.org/10.1007/s00280-013-2163-4
Titles
- Type Language Text
* Primary title English
A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Abstracts
- Text
*
PURPOSE: Long-term hormonal ablation in prostate cancer is associated with decreased overall health and quality of life. Few reports emphasized the role of chemotherapy in the management of early stage prostate cancer. This study analyzed the safety and efficacy of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for patients identified as local failures or not eligible for prostatectomy or radiation therapy due to advanced disease presentation. METHODS: Enrolled patients received ADT in the form of leuprolide every 12 weeks for 24 months with bicalutamide initiating after the completion of chemotherapy. Chemotherapy consisted of ketoconazole and doxorubicin for weeks 1, 3, and 5 and estramustine and docetaxel and for weeks 2, 4 and 6. During weeks 7 and 8, no treatment was received. RESULTS: Forty-six patients were enrolled, and forty-five patients were evaluable. Median progression-free survival (PFS) was 23.4 months. Median overall survival (OS) was 53.7 months. Out of 45 patients with measurable disease, 22 patients had an objective response: 9 patients achieved a complete response; 2 patients achieved a partial response; 10 patients achieved stable disease. Frequent grade 3 adverse events included elevated ALT (17 %), hypokalemia (13 %), and hypophosphatemia (13 %). Grade 4 adverse events were rare and included low bicarbonate (2 %), hypokalemia (2 %), leukocytopenia (2 %), and neutropenia (2 %). CONCLUSIONS: The treatment demonstrated clinical benefit in all patient subsets with minimal reversible treatment-related adverse events. Subgroup analysis suggests that having prior local therapy resulted in greater PFS and OS.

publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1432-0843, ISOAbbreviation/Cancer Chemother Pharmacol, ISSN Linking/0344-5704, Medline Title Abbreviation/Cancer Chemother Pharmacol, NLM Unique ID/7806519
title: Cancer chemotherapy and pharmacology
publisherLocation: Germany
citedMedium: Internet
volume: 71
issue: 6
articleDate: 2013-06
publicationDateText: 2013-Jun
language: English
pageString: 1629-34
publicationForm
citedMedium: Internet without issue
articleDate: 2013-04-21
webLocation
classifier: Abstract
url: https://pubmed.ncbi.nlm.nih.gov/23604530/
webLocation
classifier: DOI Based
url: https://doi.org/10.1007/s00280-013-2163-4
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Chemical
classifier: Androgen Antagonists, Anilides, Antineoplastic Agents, Hormonal, Nitriles, Tosyl Compounds, bicalutamide, KLK3 protein, human, Kallikreins, Prostate-Specific Antigen, Leuprolide
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase II, Journal Article
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Amato R
forenameInitials: R
affiliation: Division of Oncology, Department of Internal Medicine, University of Texas Health Science Center at Houston (Medical School)/Memorial Hermann Cancer Center, 6410 Fannin St., Suite 830, Houston, TX 77030, USA. robert.amato@uth.tmc.edu
entry
contributor: Stepankiw M
forenameInitials: M
entry
contributor: Gonzales P
forenameInitials: P

Generated Narrative: Practitioner #contributor0

name: Robert Amato

Generated Narrative: Practitioner #contributor1

name: Mika Stepankiw

Generated Narrative: Practitioner #contributor2

name: Patricia Gonzales

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Adenocarcinoma
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: metabolism
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Aged, 80 and over
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Anilides
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents, Hormonal
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Antineoplastic Combined Chemotherapy Protocols
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic Yes
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Disease-Free Survival
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Kallikreins
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Leuprolide
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Neoplasm Grading
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Nitriles
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Prostate-Specific Antigen
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Prostatectomy
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
- Type Classifier
* is Major topic Yes
component
type: qualifier
classifier: metabolism
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: pathology
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Radiotherapy
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Tosyl Compounds
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: administration & dosage
Components
- Type Classifier
* is Major topic No
component
type: qualifier
classifier: therapeutic use
Components
- Type Classifier
* is Major topic No
content
informationType: Classifier
type: components (if present) include qualifier codings
classifier: Treatment Failure
freeToShare: true
Components
- Type Classifier
* qualifier is not a major topic